Combined hyperfractionated radiotherapy and concurrent chemotherapy for stage Ⅲ-Ⅳ nasopharyngeal carcinoma
- VernacularTitle:超分割放射同期化疗治疗Ⅲ和Ⅳ期鼻咽癌前瞻性研究
- Author:
Hao WEN
;
Jinyi LANG
;
Jialin YANG
;
Feng XU
;
Li LIN
;
Jingbo WANG
- Publication Type:Journal Article
- Keywords:
Nasopharyngeal neoplasms/radiotherapy;
Nasopharyngeal neoplasms/chemotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
1995;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the local control and survival rates of hyperfractionated radiotherapy plus concurrent chemotherapy with hyperfractionated radiotherapy alone in the treatment of stage Ⅲ-Ⅳ nasopharyngeal carcinoma (NPC).Methods Between December 1992 and December 1995, 150 NPC patients were randomized into hyperfractionated radiotherapy plus concurrent chemotherapy (R+C) and hyperfractionated radiotherapy alone (R alone) groups. Radiotherapy were similar in the two groups: 1.2 Gy/f, twice a day. Chemotherapy was given to R+C patients before and during the course of radiotherapy. Results The overall 5-year survival (OS), disease-free survival and distant metastasis-free survival rates were 57.3%, 55.9% and 55.9% . The 5-year survival rates of the R+C and R alone groups were 64.0% and 50.7%, with the difference statistically significant (P=0.037). One patient in the R+C group and 5 patients in the R alone group developed nasopharyngeal recurrence and the corresponding 5-year local control rates were 98.7% and 93.4%. The acute mucosal reaction in the R+C patients was severer than that of the R alone, but well tolerated and did not develop any severe complications. Conclusions Hyperfractionated radiotherapy plus concurrent chemotherapy can improve the local control and survival in patients with stage Ⅲ-Ⅳ nasopharyngeal carcinoma with well tolerated mucosal reactions. Chemotherapy gives greater benefit on the survival of stage Ⅳ patients.
